BPG is committed to discovery and dissemination of knowledge
Minireviews
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
World J Clin Pediatr. Mar 9, 2026; 15(1): 111021
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.111021
Therapeutic interventions and pulmonary function in pediatric patients with post-infectious bronchiolitis obliterans
Serena Chiellino
Serena Chiellino, Department of Pediatric Emergency Medicine, Meyer Children’s Hospital IRCCS, Florence 50139, Italy
Author contributions: The author solely conceived, drafted and revised this mini review on post-infectious bronchiolitis obliterans.
Conflict-of-interest statement: The author declares that there are no conflicts of interests.
Corresponding author: Serena Chiellino, MD, Department of Pediatric Emergency Medicine, Meyer Children’s Hospital IRCCS, Viale Gaetano Pieraccini 24, Florence 50139, Italy. serena.chiellino@meyer.it
Received: June 23, 2025
Revised: July 10, 2025
Accepted: November 7, 2025
Published online: March 9, 2026
Processing time: 258 Days and 20.5 Hours
Core Tip

Core Tip: Post-infectious bronchiolitis obliterans leads to permanent small-airway obstruction and significant spirometric deficits in children, notably reduced forced expiratory volume in one second and forced expiratory flow at 25%-75% with poor bronchodilator response, while diffusing capacity of the lung for carbon monoxide often remains normal. This narrative review links these pulmonary function parameters with therapeutic interventions, showing that early use of inhaled or systemic corticosteroids and macrolides can stabilize or modestly improve lung function. Emerging combination regimens, such as fluticasone-azithromycin-montelukast, show promise but need further validation. Integrating regular spirometric monitoring with tailored anti-inflammatory strategies may optimize clinical outcomes and underlines the need for prospective studies.